COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC:CBBT), (the “Company” or “Cerebain”) today announced that it has initiated a repositioning and review of its overall business and corporate strategic plan to maximize shareholder value. The corporate strategic initiatives to be developed and implemented include, but are not limited to, a potential sale or divestiture of certain Company assets, rebranding and repositioning of the Company’s overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries. As part of the overall plan, Cerebain shall continue to pursue value-enhancing initiatives as a standalone company and a capital structure optimization policy that may involve potential financings or partnerships. To assist and advise on the development and implementation of the Company’s overall plan, it has engaged NMS Consulting, Inc., (“NMS Consulting”) an independent, global focused management consulting, corporate strategy and strategic communications firm.
In addition to a review of Cerebain’s business and corporate strategic initiatives, NMS Consulting will also advise Cerebain on a corporate restructuring and cost savings plan, under which it will identify opportunities to optimize operations, drive efficiency and reduce costs.
"We are committed to evaluating strategic alternatives that enhance value for our shareholders while maintaining our focus on the continued development of our device for the treatment of Alzheimer’s Disease as well as aggressively managing our operating expenses," said Eric Clemons, CEO of Cerebain.
While NMS Consulting has already commenced work, Cerebain has not set a definitive timetable for the process of reviewing and evaluating business and corporate strategic initiatives. There can be no assurance that these innovative pursuits will result in any immediate or particular business or strategic transaction. The Company does not intend to disclose developments or provide updates on the progress or status of this process unless and until further disclosure is appropriate or required.
About Cerebain Biotech Corp.
Cerebain Biotech Corp. (OTC:CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
About NMS Consulting, Inc.
NMS Consulting, Inc. is an independent, global focused, management consulting, corporate advisory and strategic communications firm providing strategic counsel to private and public companies, governments, philanthropic organizations and the individuals who lead them. With a global footprint, coupled with our strategic affiliations, our clients benefit from a combination of our divers skills, expertise and a global organization of seasoned professionals worldwide resulting in a unique multi-disciplinary 360⁰ solutions platform. For more information, please visit www.nmsconsulting.com.
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.